TransCode Therapeutics Inc Ordinary Shares RNAZ 深 滬
等待開盤 08-05 09:30:00 美东时间
11.40
-0.100
-0.87%
華盛通- 最 高11.635
- 今 開10.85
- 成交量 4.22万股
- 最 低 10.755
- 昨 收 11.50
- 總市值 950.30万
- 52周最高 739.20
- 市盈率 靜 --
- 換手率 5.06%
- 52周最低 6.1488
- 委 比 -47.09%
- 總股本 83.36万
- 歷史最高 5174400.00
- 量 比 0.59
- 振 幅 7.65%
- 歷史最低 6.1488
- 每 手 1
- 風險率 4.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TransCode Therapeutics Announces 2025 Annual Meeting Date
TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. TransCode Therap...
06-14 05:10
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and...
05-28 20:00
TransCode Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.
TransCode Therapeutics shares are trading lower after the company reported wors...
05-15 23:17
Reported May 14, 2025: TransCode Therapeutics Q1 EPS $(2.51) Misses $(2.00) Estimate
TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(2.51) per share which missed the analyst consensus estimate of $(2.00) by 25.5 percent. This is a 88.24 percent increase over losses of $(21.35) per
05-15 20:56
Insurers gap up, Argentine banks slide in week's biggest financial movers
Insurers surged while Argentine lenders slid this week, marking the sharpest moves across financial stocks as investors digested a deluge of corporate earnings reports. Overall, the Financial Select S...
05-03 22:10
TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall
TransCode Therapeutics (NASDAQ:RNAZ) has approved a 1-for-28 reverse stock split. The reverse stock split is intended to increase the per-share trading price of RNAZ's common stock to enable RNAZ to s...
05-03 04:23
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company")...
05-03 04:10
美股大行评级 | 潜在涨幅195.08%！Absci获Keybanc升目标价至9美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119548656129204224.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Keybanc：维持Absci(ABSI)"超配"评级，目标价从5美元升至9美元</p> <p>• Keybanc：维持AbCellera Biologics(ABCL)"超配"评级，目标价从4美元升至5美元</p> <
04-17 08:46
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer usi...
03-26 06:24
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
03-14 09:45
